发布求助
文献互助 智能选刊 最新文献

European Oncology and Haematology最新文献

筛选
英文 中文
Transient Elastography for the Detection of Hepatic Iron Overload in Patients with Myelodysplastic Syndrome 瞬时弹性成像检测骨髓增生异常综合征患者肝铁超载
European Oncology and Haematology Pub Date : 2016-01-01 DOI: 10.17925/EOH.2016.12.02.103
M. Risum, T. Barfod, K. Raaschou-Jensen
{"title":"Transient Elastography for the Detection of Hepatic Iron Overload in Patients with Myelodysplastic Syndrome","authors":"M. Risum, T. Barfod, K. Raaschou-Jensen","doi":"10.17925/EOH.2016.12.02.103","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.103","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"39 1","pages":"103"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83581831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
To hyperfractionate or not to hyperfractionate-Is it really a question? 过度分割还是不过度分割——这真的是个问题吗?
European Oncology and Haematology Pub Date : 2016-01-01 DOI: 10.17925/EOH.2016.12.01.19
J. Eriksen, M. Merlano
{"title":"To hyperfractionate or not to hyperfractionate-Is it really a question?","authors":"J. Eriksen, M. Merlano","doi":"10.17925/EOH.2016.12.01.19","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.01.19","url":null,"abstract":"Despite technical advances the last decade, patients with HPV/p16 negative head and neck cancer (being smokers and having affected performance and co-morbidities), still have a poor outcome after treatment. Hyperfractionated radiotherapy with concurrent cisplatin might be a reasonable way to pursue for improving their outcome. This strategy requires that adequate supportive care is available. The term hyperfractionated radiotherapy (HFR) is used when radiotherapy is delivered in doses below 1.8-2.0 Gy per fraction. The rationale for doing so can be found in the differences in intrinsic radiosensitivity between tumours and late responding normal tissues. A small dose per fraction will tend to increase the therapeutic ratio between tumour and critical normal tissue and therefore allow a higher tumour dose to be given at the same level of normal tissue damage. This principle been extensively explored for squamous cell carcinomas arising in the head and neck region. The of HFR","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"76 1","pages":"19-20"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83868036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimising the Use of Ruxolitinib in Inadequately Controlled Polycythaemia Vera 优化Ruxolitinib在控制不充分的Vera型红细胞增多症中的应用
European Oncology and Haematology Pub Date : 2016-01-01 DOI: 10.17925/EOH.2016.12.02.81
J. Kiladjian, Y. Francis, J. Soret
{"title":"Optimising the Use of Ruxolitinib in Inadequately Controlled Polycythaemia Vera","authors":"J. Kiladjian, Y. Francis, J. Soret","doi":"10.17925/EOH.2016.12.02.81","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.81","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"22 1","pages":"81"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75912517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Treatment Update for Women with Hormone Receptor-positive Advanced Breast Cancer 激素受体阳性晚期乳腺癌的治疗进展
European Oncology and Haematology Pub Date : 2016-01-01 DOI: 10.17925/EOH.2016.12.02.79
K. Gelmon
{"title":"Treatment Update for Women with Hormone Receptor-positive Advanced Breast Cancer","authors":"K. Gelmon","doi":"10.17925/EOH.2016.12.02.79","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.79","url":null,"abstract":"Karen Gelmon N ew treatments are needed urgently for advanced cancer of the breast, in which the most common subtype is hormone receptorpositive breast cancer. In the randomised, double-blind, multicentre phase III trial, Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer (FALCON), a statistically significant 21% reduction in the risk of disease progression or death was reported in women with hormone receptor-positive advanced breast cancer who had been treated with fulvestrant compared with those who had received anastrozole. Women in this study had not received prior hormone therapy. Access to the treatment and the mechanisms for funding need to be facilitated in a timely fashion. Ongoing studies are awaited to help define the optimal sequence of therapy for women with hormone receptor-positive advanced breast cancer.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"49 1","pages":"79"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85324668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetics in the biology and treatment of multiple myeloma 多发性骨髓瘤的生物学和治疗中的表观遗传学
European Oncology and Haematology Pub Date : 2016-01-01 DOI: 10.17925/EOH.2016.12.02.96
A. Spencer, S. Mithraprabhu
{"title":"Epigenetics in the biology and treatment of multiple myeloma","authors":"A. Spencer, S. Mithraprabhu","doi":"10.17925/EOH.2016.12.02.96","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.96","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"42 1","pages":"96-102"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78215602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to Find the Optimal Mobilisation Strategy – Impact, Challenges and Solutions 如何找到最佳的动员策略-影响，挑战和解决方案
European Oncology and Haematology Pub Date : 2016-01-01 DOI: 10.17925/EOH.2016.12.02.87
P. Wuchter, K. Hübel
{"title":"How to Find the Optimal Mobilisation Strategy – Impact, Challenges and Solutions","authors":"P. Wuchter, K. Hübel","doi":"10.17925/EOH.2016.12.02.87","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.87","url":null,"abstract":"A utologous haematopoietic stem-cell transplantation (HSCT) is the standard treatment for a number of haematological malignancies. Achieving sufficient haematopoietic stem cell mobilisation is a prerequisite, but exactly how to define and achieve this goal remains a subject of debate. Key questions include which pharmacological agents to use, timing of treatments and mobilisation, and, in particular, target numbers of stem cells. Clinicians from Europe, North America and Asia compared their experiences and discussed these issues at a satellite workshop during the 3rd International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2015). This review discusses the challenges of optimising leukapheresis in the context of these discussions. Although several studies suggest that the cell dose influences transplant outcomes in HSCT, other studies have not reached this conclusion. Recent data indicate that the graft composition also plays a role. More prospective study data are needed for a fuller understanding of engraftment outcomes using different mobilisation protocols.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"236 1","pages":"87"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88562915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prevention of Chronic Graft-versus-host Disease and the Unique Role of Anti-human T-lymphocyte Immune Globulin 慢性移植物抗宿主病的预防及抗人t淋巴细胞免疫球蛋白的独特作用
European Oncology and Haematology Pub Date : 2016-01-01 DOI: 10.17925/EOH.2016.12.02.93
N. Kröger
{"title":"Prevention of Chronic Graft-versus-host Disease and the Unique Role of Anti-human T-lymphocyte Immune Globulin","authors":"N. Kröger","doi":"10.17925/EOH.2016.12.02.93","DOIUrl":"https://doi.org/10.17925/EOH.2016.12.02.93","url":null,"abstract":"C hronic graft-versus-host disease (GVHD) is a major cause of late morbidity and mortality post-allogeneic haematopoietic stemcell transplantation. Compared with acute GVHD, for which progress in preventative measures have been made, chronic GVHD describes a more diverse syndrome, and may adversely affect almost all organs in the body. A new prospective, multicentre, open-label, randomised phase III study (n=168) showed that the use of anti-human T-lymphocyte immune globulin (ATLG) in a myeloablative conditioning regimen for patients with acute leukaemia led to a significantly lower rate of chronic GVHD post-allogeneic transplantation compared with those receiving the same regimen without ATLG. Importantly, no increased rate of relapses in the patients who received ATLG was seen compared with those who did not. Thus, there was no apparent impairment in the graft-versus-leukaemia effect in ATLG-treated patients. The study was terminated at 2 years and more evidence about the long-term effect of ATLG on survival and GVHD relapses beyond this time-point are needed. Nonetheless, the findings represent a significant advance in the prevention of chronic GVHD.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"11 1","pages":"93"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85803456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic Myeloid Leukaemia - The Choice of Therapy and Future Perspectives 慢性髓性白血病-治疗的选择和未来的展望
European Oncology and Haematology Pub Date : 2015-06-01 DOI: 10.17925/EOH.2015.11.01.25
A. Carella, Clara Dellepiane, Davide Lovera, A. Ibatici, C. Ghiggi, A. Carella, G. Beltrami
{"title":"Chronic Myeloid Leukaemia - The Choice of Therapy and Future Perspectives","authors":"A. Carella, Clara Dellepiane, Davide Lovera, A. Ibatici, C. Ghiggi, A. Carella, G. Beltrami","doi":"10.17925/EOH.2015.11.01.25","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.01.25","url":null,"abstract":"Recently, the advent of imatinib has opened a new era in the treatment of chronic myeloid leukaemia (CML), leading to an impressive increase in overall survival rates. Today, many CML patients can expect to survive, if properly managed, likely similar to the general population. Recent progresses in CML stem cell biology have identified new leukogenetic pathways and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives in CML therapy and have highlighted major strategies for treating, and possibly eradicating, CML in the upcoming years.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"14 1","pages":"25-29"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81002027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A Rare Condition in Haematological Practice – Gaucher Disease 血液学实践中一种罕见的疾病——戈谢病
European Oncology and Haematology Pub Date : 2015-06-01 DOI: 10.17925/EOH.2015.11.01.15
M. Cappellini
{"title":"A Rare Condition in Haematological Practice – Gaucher Disease","authors":"M. Cappellini","doi":"10.17925/EOH.2015.11.01.15","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.01.15","url":null,"abstract":"Touch MEDical MEDia 15 Abstract Gaucher disease, which is caused by an inherited glucocerebrosidase deficiency, is the most prevalent lysosomal storage disease worldwide. Estimated prevalence of Gaucher disease is 1:50,000 in most countries and the disease has its highest incidence in the Ashkenazi Jewish population. Type 1 (non-neuropathic) Gaucher disease is by far the most common form. Gaucher disease type 1 should be considered in cases of unexplained splenomegaly with or without bleeding diathesis, skeletal manifestations or hepatomegaly. Diagnosis is made by demonstrating decreased glucocerebrosidase activity in peripheral blood leucocytes. Dried blood spots can be used for screening but conventional enzyme assay on heparinised blood is essential. Patients with Gaucher disease may have extensive organ involvement despite relatively minor overt symptomatology. Evidence suggests that Gaucher disease may remain undiagnosed for years, leading to severe complications that are preventable or reversible with enzyme replacement therapy. These complications include avascular necrosis, severe bleeding, chronic bone pain, pathological fractures, growth failure, liver pathology and life-threatening sepsis. Most patients with Gaucher disease are initially evaluated by a haematologist–oncologist. Improved education is needed to enable prompt detection of Gaucher disease. An increased risk of multiple myeloma and haematological and non-haematological malignancies has been reported in type 1 Gaucher disease. This review aims to offer familiarisation with a rare disorder in haematological practice, focusing on adult patient management.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"110 1","pages":"15-20"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76670961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Breast Cancer Patients Continue to Struggle for Years After Diagnosis 乳腺癌患者在确诊后仍要与疾病抗争数年
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.01.39
E. Pennery
{"title":"Breast Cancer Patients Continue to Struggle for Years After Diagnosis","authors":"E. Pennery","doi":"10.17925/EOH.2015.11.01.39","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.01.39","url":null,"abstract":"Disclosure: Emma Pennery is an employee of Breast Cancer Care. No funding was received in the publication of this article. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit. Received: 6 February 2015 Accepted: 6 February 2015 Citation: European Oncology & Haematology, 2015;11(1):39–40 Correspondence: Emma Pennery, Breast Cancer Care, 5–13 Great Suffolk Street, London SE1 0NS, UK. E: info@breastcancercare.org.uk Breast Cancer Patients Continue to Struggle for Years After Diagnosis","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"120 1","pages":"39"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81680230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信